Introduction
The poor 5-year survival probability of 15% for patients with hepatocellular carcinoma (HCC) is due, in part, to the delayed diagnosis -only 39% of patients with HCC in the U.S. are diagnosed at an early stage (1) . Treatment modalities, such as trans-arterial chemoembolization (TACE), have been shown to be effective in lengthening survival (2) ; however, the limited efficacy in stage 3 or 4 HCC and risk of compromising the hepatic blood supply limits its use, particularly in patients with decompensated cirrhosis (3) . A number of systemic agents have been evaluated, with sorafenib showing the greatest benefit, but its use is limited to advanced HCC (4) . There remains a need for an additional systemic therapeutic agent that improves the outcomes for HCC patients.
HMG-CoA reductase inhibitors, also known as statins, are commonly prescribed to control cholesterol levels. Mechanistic studies demonstrate that statin not only has cholesterol-lowering effects, but also anti-proliferative effects on cancer cells, through reduced production of isoprenoid (e.g. farnesyl pyrophostate, geranyl pyrophosphate), a post-translational modifier of the RAS protein. Statin-induced reduction in isoprenoids activates the Raf-MEK-ERK and the PI3K-AKT-mTOR pathways essential to survival of cancer cells (5) and also inhibits the replication of hepatitis C virus (HCV) (6) . Accordingly, statins have been shown to improve the anti-viral activity of HCV polymerase and protease inhibitors in vitro (7) , and are associated with an enhanced virologic response to peginterferon and ribavirin therapy in humans (8) . In line with these pleotropic effects, statins have been reported to decrease the risk of HCC (9, 10) . A clinical trial also found a 9 month improvement in survival among advanced HCC patients treated with pravastatin (11) . It remains unknown however, whether statins lengthen survival in patients with non-advanced HCC.
Not all statins are expected to have a specific local effect on the liver, as each varies in hepatoselectivity.
Hydrophilic statins, such as pravastatin, accumulate in the liver via carrier-mediated transporters that are expressed in hepatocytes. As a consequence, hydrophilic statins are unable to enter cells in extrahepatic tissue that lacks the transporter. By contrast, lipophilic statins, such as simvastatin, enter cells in the liver and in the extrahepatic tissue via passive diffusion. The non-discriminating uptake results in less accumulation in the liver (12) . We hypothesized that hydrophilic statins may provide enhanced prognostic benefit to HCC patients in comparison to lipophilic statins based on their hepatoselective properties.
Our objective was to investigate whether there is a beneficial impact of statin use on overall survival in HCC patients in a population-based database of elderly patients with cancer. Given the in vitro evidence for anti-HCV activity, we also examined variability in the association of statin with HCC survival by HCV infection. Furthermore, considering the hepatoselective nature of hydrophilic statins, we investigated the impact of statin on survival by lipophilic classification.
Materials and Methods
We constructed a retrospective cohort of Medicare-insured HCC patients represented in the Surveillance, 
Medicare Data

Statin treatment
Exposure to statins after cancer diagnosis was assessed both as a binary variable (ever use after cancer diagnosis vs. never use), and as an ordinal variable (high, moderate, low intensity vs. never use). Those taking statin at the time of or after the cancer diagnosis were considered to be statin users. Data on statin prescriptions were extracted from the prescription drug event file that details the timing, type and dose of each prescription filled by Medicare Part D enrollees. High, moderate and low intensity statin therapy followed the categorizations set forth by the American Heart Association and the American College of
Cardiologists (14) . Atorvastatin, pravastatin and rosuvastatin were categorized as hydrophilic statins, while fluvastatin, lovastatin, and simvastatin were categorized as lipophilic statins. 
Covariates
Data on resection of the liver, liver transplantation, radiofrequency ablation, and TACE were extracted through the Medicare inpatient files using ICD9 procedure codes. Diagnoses of cardiovascular disease, (i.e. myocardial infarction, stroke, peripheral artery disease), cirrhosis, dyslipidemia, diabetes, and obesity, were extracted through the ICD9 diagnostic codes in the Medicare claims files from inpatient and outpatient records. ICD9 procedures codes and Common Procedural Terminology (CPT) codes for percutaneous coronary intervention, coronary artery bypass graft or carotid revascularization procedure were also used to identify HCC patients with cardiovascular disease. All procedural and diagnostic codes are available as a supplement (Supplementary Methods and Materials).
Statistical analyses
We described the distribution of demographic, clinical and comorbid factors by statin use after cancer diagnosis, and compared the frequencies between statin users and non-users by Chi-square analysis. We also summarized the frequency and incidence rate of death per 100 person-years observed, and tested for differences in survival between variable attributes using the log-rank test. The strength of the association between statin use and survival was evaluated by Cox proportional hazards regression, using several modeling approaches: 1) a bi-variable model incorporating statin as a static variable, treating those who had taken any statin after cancer diagnosis as users from the beginning of follow-up; 2) a bi-variable model incorporating statin as a time-dependent variable, in which those who were already on statin were considered users from the beginning of follow-up, while those who were not on statin but used statin later were considered non-users until the first prescription after cancer diagnosis; 3) a multivariable model with statin as a time-dependent variable, adjusting for all covariates considered above; and 4) a multivariable model with statin as a time-dependent variable lagged by two months to remove potential bias from endof-life decisions that influenced statin disuse. A time-dependent model was used specifically to remove bias due to immortal time, that is, the non-event period between diagnosis and statin initiation. We also examined the impact of different types of statin by simultaneously modeling atorvastatin, lovastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin as independent time-dependent variables lagged by 2 months, adjusting for all covariates. Potential difference in the hazard of death by lipophilicity of statin was investigated by simultaneously modeling hydrophilic and lipophilic statins also as independent variables. Dose response by statin intensity was examined by multivariable time-dependent analyses.
A secondary aim was to examine the statin-survival association by HCV infection status given the purported influence of statin on HCV replication, and virologic response to HCV treatment (6) (7) (8) . We performed subgroup analyses by HCV infection status, and tested for effect modification by a two-way interaction term between statin and HCV using the likelihood ratio test. We also examined the following covariates as potential effect modifiers of the statin-survival association: age, grade, tumor size and stage, resection, cardiovascular disease, cirrhosis, obesity, dyslipidemia, and hepatitis B infection. This study was approved by the Institutional Review Board at Cedars-Sinai Medical Center. This study employed a limited data set without direct identifiers and therefore did not require consent from patients.
Results
Of the 1036 patients included in the analysis, 363 were using statin either at the time of cancer diagnosis or following their cancer diagnosis. The statin users were more likely to be 75 years or older (54% vs. 43%), male (71% vs. 61%), or be diagnosed with cardiovascular disease (59% vs. 42%), obesity (14%, vs. 9%), dyslipidemia (71% vs. 54%), or diabetes (60%, vs. 48%) compared to HCC patients without a statin prescription. The statin users were less likely to have received a liver transplantation (3.9% vs. 7.7%) and to have a diagnosis of HCV infection (19% vs. 35%) compared to non-users. (Table 1) There were 584 deaths among HCC patients with a median survival of 21 months. Those who were treated with statin had a longer median survival compared to those not treated with statin: (23.9 vs. 18.9 months, (p for log-rank test = 0.047). B or C infection were associated with a lower rate of death, whereas being 75 years or older, black, living in a neighborhood with median income of <$50,000, having a higher tumor grade and stage at diagnosis, and hypertension were associated with a greater rate of death (Table 2) . Table 3 We performed several analyses to examine different effects of statin types and intensity on survival in HCC patients. The most commonly used statin was simvastatin (49% of statin users), followed by atorvastatin (35%), lovastatin (23%), pravastatin (13%), and rosuvastatin (8.5%). The majority of statin users were on lipophilic statins (88%) and on moderate dose (68%). We found that there was no particular statin compound, type or intensity that were significantly associated with increased survival. Of note, a trend towards lower hazard of death was observed for pravastatin users (HR = 0.82, 95%CI 0.50, 1.34), but the association was not statistically significant. Neither hydrophilic statin (HR = 0.80, 95% CI 0.54, 
1.19) nor lipophilic statin (HR = 1.03, 95%CI 0.84, 1.26) was associated with survival; and dose-response was not observed (Table 5) .
Discussion
In an analysis of over 1000 elderly patients with stage I/II HCC represented in SEER-Medicare, we found that statin use after cancer diagnosis was not associated with survival. Our finding did not vary by HCV infection status, nor by any other comorbid conditions that we considered. Additionally, we did not find that pravastatin, previously reported to increase survival in advanced HCC patients, was significantly associated with increased survival in this cohort. This is the first population-based investigation of the impact of statin use on overall survival in elderly patients with HCC and the first investigation regarding the utility of statin in non-advanced HCC patients. Our finding is therefore generalizable to patients with stage early stage HCC in an elderly population living in the U.S.
Our results stand in contrast to that of a randomized clinical trial examining the impact of pravastatin on survival among patients with advanced HCC (11) . Results from this clinical trial demonstrated that pravastatin increased survival by 9 months (18 months in pravastatin vs. 9 months in placebo) and that tumor growth was slower in HCC patients treated with pravastatin. Pravastatin is a hydrophilic statin, which is taken up by hepatocytes by carrier-mediated transporters and therefore accumulates in the liver (12) . Because of this hepatoselective property and the previous clinical trial finding, we hypothesized that pravastatin would be associated with greater survival in this population of elderly patient with nonadvanced HCC. In our study, the hazard ratio attributable to pravastatin was 0.82, thus pointing to a potentially beneficial impact of this hydrophilic statin, but the association was not statistically significant and much weaker than determined in the clinical trial (12) . Our study differs from the clinical trial of pravastatin treatment in advanced HCC patients in that this is an observational study, of elderly patients 65 years or older with stage I or II HCC. Thus, both methodological and population differences could have led to differences in the results. Elderly patients may derive less benefit from chemotherapeutic The strength of our study is that we analyzed a large sample of HCC patients, and that our study findings are generalizable to the U.S. elderly with HCC. Secondly, we had detailed prescription filling information with provision of timing, dose and type of statin treatment. Furthermore, we were able to Those with more severe liver disease would have had a lower level of cholesterol leading to less frequent statin use. Both unmeasured confounders would have biased the results towards an apparent protective effect of statin, which we did not observe. Our study was also underpowered to detect a statistically significant relationship for pravastatin.
In summary, we found that statin use after cancer diagnosis was not associated with survival in elderly patients with stage I-II hepatocellular carcinoma with or without hepatitis C. Further studies in younger patients should be conducted to determine the true effect of statin in the HCC population. 
